Verve Therapeutics to Participate in Upcoming May Investor Conferences

Rhea-AI Summary

Verve Therapeutics has announced that its CEO, Sekar Kathiresan, will participate in two significant investor conferences in May 2022. The first is the BofA Securities 2022 Healthcare Conference on May 11 at 2:40 p.m. PT in Las Vegas, followed by a fireside chat at the RBC Capital Markets Global Healthcare Conference on May 18 at 1:35 p.m. ET in NYC. Live webcasts of both events will be accessible on the company’s website and archived for 60 days. Verve focuses on gene editing medicines to treat cardiovascular disease, with its lead product candidate, VERVE-101, targeting the PCSK9 gene to lower LDL-C levels.

CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in the following May investor conferences:

• BofA Securities 2022 Healthcare Conference (formal presentation) on Wednesday, May 11, 2022, at 2:40 p.m. PT in Las Vegas; and,
• 2022 RBC Capital Markets Global Healthcare Conference (fireside chat) on Wednesday, May 18, 2022, at 1:35 p.m. ET in NYC.

Live webcasts will be available in the investor section of the company's website at www.vervetx.com and will be archived for 60 days following the presentations.

About Verve Therapeutics
Verve Therapeutics, Inc. (Nasdaq: VERV) is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company’s initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol (LDL-C), a root cause of cardiovascular disease. Verve’s lead product candidate, VERVE-101, is designed to permanently turn off the PCSK9 gene in the liver in order to disrupt blood PCSK9 protein production and thereby durably reduce blood LDL-C levels, with the goal of reducing a patient’s risk for cardiovascular disease. VERVE-101, currently in IND-enabling studies, is being developed initially for the treatment of patients with heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease. For more information, please visit www.VerveTx.com.

Investor Contact
Jen Robinson
Verve Therapeutics, Inc.
jrobinson@vervetx.com

Media Contact
Gina Nugent
Ten Bridge Communications
gina@tenbridgecommunications.com

FAQ

What investor conferences is Verve Therapeutics participating in May 2022?

Verve Therapeutics will participate in the BofA Securities 2022 Healthcare Conference on May 11 and the RBC Capital Markets Global Healthcare Conference on May 18, 2022.

What is the goal of Verve Therapeutics' VERVE-101?

VERVE-101 aims to permanently turn off the PCSK9 gene to reduce low-density lipoprotein cholesterol (LDL-C) levels, thereby decreasing cardiovascular disease risk.

Where can I watch the live presentations by Verve Therapeutics?

Live webcasts of Verve Therapeutics' presentations will be available on their investor website and will be archived for 60 days after the events.

What is Verve Therapeutics' focus in the biotechnology sector?

Verve Therapeutics focuses on developing single-course gene editing medicines to treat cardiovascular disease.

When will the BofA Securities 2022 Healthcare Conference take place?

The BofA Securities 2022 Healthcare Conference is scheduled for May 11, 2022, at 2:40 p.m. PT.